BioCentury
ARTICLE | Distillery Therapeutics

Cancer

December 19, 2017 8:58 PM UTC

Mouse studies suggest inhibiting CCR2 in combination with radiotherapy could help treat colon and lung cancers. In mouse models of colon and lung cancers, systemic knockout of CCR2 plus radiation decreased tumor growth compared with normal CCR2 expression plus radiation. In the colon cancer model, an anti-CCR2 antibody plus radiation decreased tumor growth compared with a control IgG plus radiation. Next steps could include testing the combination of CCR2 inhibitors and radiation treatment in xenograft models of colorectal and lung cancers.

ChemoCentryx Inc. and Vifor Pharma Ltd. have CCX140, an inhibitor of CCR2, in phase II testing to treat diabetic nephropathy and in preclinical testing to treat focal segmental glomerulosclerosis (FSGS)...